Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up – Still a Buy?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) shares gapped up prior to trading on Thursday . The stock had previously closed at $37.00, but opened at $45.01. Enliven Therapeutics shares last traded at $41.8640, with a volume of 1,466,401 shares trading hands.

Enliven Therapeutics News Summary

Here are the key news stories impacting Enliven Therapeutics this week:

• Positive Sentiment: Enliven reported updated Phase 1 ENABLE trial data for ELVN-001 in previously treated chronic myeloid leukemia, showing encouraging response rates, a favorable safety profile, and continued momentum for its clinical program. Article Title
• Positive Sentiment: The company also said it reached alignment with the FDA on key Phase 3 design elements, including the recommended dose and patient population for the upcoming ENABLE-2 trial, reducing regulatory uncertainty around the program. Article Title
• Neutral Sentiment: Enliven discussed the updated Phase 1 ENABLE trial data in a presentation/transcript, reinforcing investor focus on the clinical details behind the recent share move. Article Title
• Neutral Sentiment: The company priced an upsized public offering of common stock and pre-funded warrants, raising roughly $400 million, which strengthens the balance sheet but may dilute existing shareholders. Article Title
• Negative Sentiment: Enliven also initially announced the offering at a lower size before upsizing it, underscoring the near-term dilution overhang that can pressure the stock even amid positive trial news. Article Title

Analyst Upgrades and Downgrades

ELVN has been the subject of several analyst reports. Mizuho boosted their target price on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. Guggenheim initiated coverage on shares of Enliven Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $80.00 price objective for the company. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. HC Wainwright upped their price objective on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Finally, Stifel Nicolaus initiated coverage on shares of Enliven Therapeutics in a research report on Tuesday. They set a “buy” rating and a $60.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.50.

Enliven Therapeutics Price Performance

The firm has a market cap of $2.81 billion, a PE ratio of -27.62 and a beta of 0.29. The stock’s fifty day moving average price is $41.47 and its 200-day moving average price is $30.72.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. On average, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.71 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Lori Anne Kunkel sold 10,000 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $34.54, for a total transaction of $345,400.00. Following the completion of the sale, the director owned 51,884 shares of the company’s stock, valued at $1,792,073.36. This represents a 16.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Enliven Therapeutics

A number of large investors have recently modified their holdings of ELVN. KBC Group NV purchased a new stake in shares of Enliven Therapeutics during the first quarter worth $38,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after buying an additional 594 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares during the period. Los Angeles Capital Management LLC purchased a new stake in shares of Enliven Therapeutics in the fourth quarter valued at about $83,000. Finally, Quantbot Technologies LP grew its holdings in shares of Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.